Century Therapeutics, Inc.

General Information

We are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. We have created a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows us to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, our proprietary Allo-EvasionTM technology intended to prevent rejection of our cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. We believe that these vertically integrated capabilities will allow us to further expand our existing pipeline and develop therapeutics from iPSC-derived natural killer cells, or iNK cells, or iNK, and iPSC-derived T cells, or iT cells, or iT, that may provide enhanced clinical outcomes compared to available therapeutic options. Our vision is to become a premier cell therapy company by developing and ultimately commercializing allogeneic cell therapies that dramatically and positively transform the lives of patients suffering from life-threatening cancers. To achieve our vision, we have assembled a world-class team whose members collectively have decades of experience in cell therapy and drug development, manufacturing, and commercialization.

With the exception of our lead product candidate, CNTY-101, each of our product candidates is designed to target multiple tumor antigens. We currently anticipate filing an IND for our lead product candidate, CNTY-101, targeting B-cell lymphoma, in mid 2022. Our second product candidate, CNTY-103, is designed to treat glioblastoma, and we currently anticipate filing an IND in the first half of 2023. Our third product candidate, CNTY-102, is designed to further improve B-cell malignancy treatment, and we are planning on filing an IND for it in the second half of 2023. Our fourth product candidate, CNTY-104, is being developed to treat AML with the IND filing expected in mid 2024.

(Note: Century Therapeutics priced its IPO on June 17, 2021, at $20 – the top of its range – on 10.55 million shares to raise $211 million.)

Employees: 107
Founded: 2018
Contact Information
Address 3675 Market Street Philadelphia, Pennsylvania 19104
Phone Number (267) 817-5790
Web Address http://www.centurytx.com/
View Prospectus: Century Therapeutics, Inc.
Financial Information
Market Cap $1041.58mil
Revenues $0 mil (last 12 months)
Net Income $-53.58 mil (last 12 months)
IPO Profile
Symbol IPSC
Exchange NASDAQ
Shares (millions): 10.6
Price range $20.00 - $20.00
Est. $ Volume $211.0 mil
Manager / Joint Managers J.P. Morgan/ BofA Securities/ SVB Leerink/ Piper Sandler
CO-Managers -
Expected To Trade: 6/18/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change